

Balaxi Pharmaceuticals Limited

Date: 31st July, 2026

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Subject: Business Responsibility and Sustainability Report of the Company for the FY 2025-26

Dear Sir / Madam,

Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the 'Business Responsibility and Sustainability Report' ("BRSR") of Balaxi Pharmaceuticals Limited ("the Company") for the Financial Year 2025-26, which forms part of the Annual Report of the Company for the Financial Year 2025-26.

The Annual Report of the Company for the Financial Year 2025-26 containing BRSR Report for the said financial year are available on the Company's website at:

https://balaxipharma.in/assets/images/articles/Balaxi_Annual_Report_2025-26.pdf

This is for your information and record.

Thanking You.

Yours faithfully,
For Balaxi Pharmaceuticals Limited

Aman Purohit
(Company Secretary & Compliance Officer)
ICSI Membership No.: A59345

(Encl: As above)

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

Business Responsibility & Sustainability Report

(For the Financial Year ended 31st March, 2026)

Section A) General Disclosures

I. Details of the listed entity

1.	Corporate Identity Number (CIN) of the Listed Entity	L25191TG1942PLC121598
2.	Name of the Listed Entity	BALAXI PHARMACEUTICALS LIMITED
3.	Year of incorporation	1942
4.	Registered office address	PLOT No.409, H.No: 8-2-293, Maps Towers, 3 rd Floor, Phase-III, Road No.81, Jubilee Hills, Hyderabad, Telangana – 500096, India.
5.	Corporate address	PLOT No.409, H.No: 8-2-293, Maps Towers, 3 rd Floor, Phase-III, Road No.81, Jubilee Hills, Hyderabad, Telangana – 500096, India.
6.	E-mail	secretarial@balaxi.in
7.	Telephone	+91 40 2355 5300
8.	Website	www.balaxipharma.in
9.	Financial year for which reporting is being done	April 2025- March 2026
10.	Name of the Stock Exchange(s) where shares are listed	National Stock Exchange of India Limited
11.	Paid-up Capital	Rs. 11,04,15,000 (Rupees Eleven Crores Four Lakhs and Fifteen Thousand Only)
12.	Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report	Mr. Aman Purohit, Company Secretary and Compliance Officer, Telephone: +91 40 2355 5300, Email: secretarial@balaxi.in
13.	Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together)	The disclosure under this report has been made on a Standalone basis.
14.	Name of the assessment or assurance provider	Not Applicable
15.	Type of assessment or assurance obtained	Not Applicable

II. Product & Services

16. Details of business activities (accounting for 90% of the turnover):

S No	Description of Main Activity	Description of Business Activity	% of turnover of the entity
1	Trading	International Wholesale trading/distribution	100%

17. Products/Services sold by the entity (accounting for 90% of the entity's turnover

S No	Product /Service	NIC Code	% of the total turnover contributed
1	Pharmaceutical Products	464	100.00

III. Operations

18. Number of locations where plants an/or operations/offices of the entity are situated

Location	Number of Plants	Number of Offices	Total
National	1*	1	2
International	-	-	-

*Manufacturing facility has been established in which operations are expected to commence in H1 of FY 2026-27.

19. Markets served by the entity:

a. Number of Locations

Locations	Number
National (No. of States)	-
International (No. of Countries)	6

b. What is the contribution of exports as a percentage of the total turnover of the entity ? 100%

c. A brief on types of customers : Local distributors, Pharmacies, Government Hospitals, Government Tenders and other NGO Tenders.

IV. Employees

20. Details at the end of Financial Year

a. Employees and workers (including differently abled):

SL No.	Particulars	Total	Male		Female	
		(A)	No. (B)	% (B/A)	No. (C)	% (C/A)
Employees						
1	Permanent(D)	62	51	82.26	11	17.74
2	Other than permanent(E)	-	-	-	-	-
3	Total Employees (D+E)	62	51	82.26	11	17.74
Workers						
4	Permanent(F)	7	6	85.71	1	14.29
5	Other than permanent(G)	-	-	-	-	-
6	Total Employees(F+G)	7	6	85.71	1	14.29

b. Differently Abled Employees & Workers

SL No.	Particulars	Total (A)	Male		Female	
			No. (B)	% (B/A)	No. (C)	% (C/A)
Differently Abled Employees						
1	Permanent(D)	-	-	-	-	-
2	Other than permanent(E)	-	-	-	-	-
3	Total Employees(D+E)	-	-	-	-	-
Differently Abled Workers						
4	Permanent(F)	-	-	-	-	-
5	Other than permanent(G)	-	-	-	-	-
6	Total Employees(F+G)	-	-	-	-	-

21. Participation/Inclusion/Representation of Women

Particulars	Total	No. and percentage of Females	
	(A)	No.(B)	% (B/A)
Board of directors	6	2	33.33
Key Management Personnel	4	0	0

22. Turnover rate for permanent employees and workers.

(Disclose trends for the past 3 years)

	Turnover Rate-FY2026			Turnover Rate-FY2025			Turnover Rate-FY2024		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Permanent Employees	33.33%	44.44%	35.08%	15%	42.86%	20.45%	39%	33%	30.43%
Permanent Workers	142.86%	0	125%	-	-	-	-	-	-

V. Holding, Subsidiary and Associate Companies (Including joint ventures)

23.(a) Names of holding/subsidiary/associate companies/joint ventures

S. No.	Name of the holding / subsidiary / associate companies / joint ventures (A)	Indicate whether Holding/ Subsidiary/ Associate/ Joint Venture	% of shares held by listed entity	Does the entity indicated at column A, participate in the Business Responsibility initiatives of the listed entity? (Yes/No)
1	Balaxi Overseas Private Limited	Holding Company	Not Applicable	No
2	Balaxi Global FZCO, Dubai (Formerly known as Balaxi Global DMCC, Dubai)	Wholly owned subsidiary	100%	No
3	Balaxi Healthcare Ecuador S.A.S.	Wholly owned subsidiary	100%	No
4	Balaxi Healthcare Guatemala, S.A., Republic of Guatemala	Wholly owned Step-down subsidiary	100%	No
5	Balaxi Healthcare Dominicana, S.R.L., Dominican Republic	Wholly owned Step-down subsidiary	100%	No
6	Balaxi Healthcare Honduras, S.DE R.L.DE C.V Honduras	Wholly owned Step-down subsidiary	100%	No
7	Balaxi Healthcare El Salvador S.A DE., El Salvador	Wholly owned Step-down subsidiary	100%	No
8	Balaxi Healthcare Angola, Republic of Angola	Wholly owned Step-down subsidiary	100%	No
9	Balaxi Healthcare Nicaragua	Wholly owned Step-down subsidiary	100%	No

Note: Balaxi Healthcare Centrafrique, SARL, Centrafrique has been struck off during the financial year 2025-26 and ceased to be a Wholly owned Step-down subsidiary with effect from 10th April, 2025.

During the financial year under review, Balaxi Healthcare Nicaragua was acquired as a wholly owned subsidiary of Balaxi Global FZCO with effect from 01st April, 2025.

Note: Balaxi Global FZCO, Wholly Owned Subsidiary of the Company holds 100% of shares in the step-down subsidiaries.

Balaxi Overseas Private Limited is Holding Company of the listed entity and it holds 63.40% of the total equity shares of the Company.

VI. CSR Details

24. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013: (Yes/No) :Yes
(ii) Turnover (in Rs.): 8,085.11 Lakhs
(iii) Net Worth (in Rs.): 13,300 Lakhs

VII. Transparency and Disclosures Compliances

25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct:

Stakeholder Group from whom complaint is received	Grievance Redressal Mechanism in Place. Yes/No (If Yes, then provide web-link for grievance redress policy)	FY 2026			FY 2025		
		Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Communities	Yes https://balaxipharma.in/corporate-policies	Nil	Nil		Nil	Nil	

Stakeholder Group from whom complaint is received	Grievance Redressal Mechanism in Place. Yes/No (If Yes, then provide web-link for grievance redress policy)	FY 2026			FY 2025		
		Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Investors (Other than Shareholders)	Yes https://balaxipharma.in/corporate-policies	Nil	Nil		Nil	Nil	
Shareholders	Yes https://balaxipharma.in/corporate-policies	Nil	Nil		Nil	Nil	
Employees & Workers	Yes https://balaxipharma.in/corporate-policies	Nil	Nil		Nil	Nil	
Customers	Yes https://balaxipharma.in/corporate-policies	Nil	Nil		Nil	Nil	
Value Chain Partners	Yes https://balaxipharma.in/corporate-policies	Nil	Nil		Nil	Nil	
Other (Please specify)	--						

26. Overview of the entity's material responsible business conduct issues

Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, the rationale for identifying the same, approach to adapt or mitigate the risk along with its financial implications, as per the following format

SL No	Material Issue Identified	Indicate whether Risk / Opportunity (R/O)	Rational for identifying risk or opportunity	In case of risk, approach to adapt or mitigate	Financial implication of risk or opportunity (Indicate positive or negative implications)
1	Carbon Footprint in Global Supply Chain	Risk	Climate change will result in stricter environmental regulations across sectors, this will increase transportation cost for the Company.	Ensuring Vendors/ CDMOs are in compliance with the applicable environmental standards.	Negative: Increased operating costs in meeting the environmental standards.
2	Diversity and Inclusion	Opportunity	Foster a diverse and inclusive workplaces that promotes equality, non-discrimination, and equal opportunities for all employees. this will lead to a good talent pool for the company	-	Positive implication: the productivity will increase due to healthy work environment
3	Corporate Governance	Opportunity	Ensuring a good governance and transparent practices can help securing stakeholder interest, a higher reputation, reduced risks, and improved financial performance.		Positive implication: Reduced risk due to transparent practices

SECTION B: Management and Process Disclosures

This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the NGRBC Principles and Core Elements.

Disclosure Questions		P1	P2	P3	P4	P5	P6	P7	P8	P9	
Policy and Management Processes											
1. a.	Whether your entity's policy/policies cover each principle and its core elements of the NGRBCs. (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
b.	Has the policy been approved by the Board? (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
c.	Web Link of the Policies, if available	https://balaxipharma.in/corporate-policies									
2.	Whether the entity has translated the policy into procedures. (Yes / No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
3.	Do the enlisted policies extend to your value chain partners? (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
4.	Name of the national and international codes/certifications/ labels/ standards (e.g. Forest Stewardship Council, Fairtrade, Rainforest Alliance, Trustea) standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted by your entity and mapped to each principle.	1.	Government of Telangana Electrical Inspectorate: Lr. No.DyCEIG-Hyd/TG/EI Ex.650V/HT-MBN-2025-20045/D.No.: 16/08/2025.								
		2.	Certificate of Consent for Establishment under the Orange Category from the Telangana State Pollution Control Board, Zonal Office, Hyderabad. Order No.: 1059-MBNR/TSPCB/ZOH/TS-Ipass/CFO/2025-1585.								
		3.	Government of India Ministry of commerce and industry for Petroleum and Explosives safety organisation (PESO) PESO/FPS/2025/6801/(G154501)								
5.	Specific commitments, goals and targets set by the entity with defined timelines, if any.	The Company is determined to follow the path envisioned under the 9 principles laid down in the National Voluntary Guidelines on Social, Environmental & Economic Responsibilities of Business issued by the Ministry of Corporate Affairs									
6.	Performance of the entity against the specific commitments, goals and targets along-with reasons in case the same are not met.	The Company shall continue to monitor its performance against the said principle(s) and take necessary action as and when the need arises									
Governance, leadership and oversight											
7.	Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements (listed entity has flexibility regarding the placement of this disclosure) The purpose of our business is to dedicatedly serve to ensure stakeholder delight and influence the environment and society at large with our good work, as we abide by our values that form the cornerstone of our business strategies, decisions, and activities. We are committed to this roadmap as we seek to grow sustainably and deliver Pharmaceutical Products to frontier markers with excellence, again and again, with a lot more rigor and enthusiasm as the days pass.										
8.	Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy (ies).	Mr.Ashish Maheshwari (DIN:01575984), Managing Director Telephone:+9140 23555300 Email:secretarial@balaxi.in									
9.	Does the entity have a specified Committee of the Board/ Director responsible for decision making on sustainability related issues? (Yes / No). If yes, details.	Yes, the Committee consists of Managing Director as Chairman along with other functional heads.									

10. Details of Review of NGRBCs by the Company:

Subject for Review	Indicate whether review was undertaken by Director / Committee of the Board/ Any other Committee									Frequency (Annually/ Half yearly/ Quarterly/ Any other – please specify)								
	P1	P2	P3	P4	P5	P6	P7	P8	P9	P1	P2	P3	P4	P5	P6	P7	P8	P9
Performance against above policies and follow up action	Y	Y	Y	Y	Y	Y	Y	Y	Y									Half Yearly
Compliance with statutory requirements of relevance to the principles, and, rectification of any non-compliances	Y	Y	Y	Y	Y	Y	Y	Y	Y									Quarterly
11. Has the entity carried out independent assessment/ evaluation of the working of its policies by an external agency? (Yes/No). If yes, Name of the agency.	P1	P2	P3	P4	P5	P6	P7	P8	P9	N	N	N	N	N	N	N	N	N

12. If answer to question (1) above is “No” i.e. not all Principles are covered by a policy, reasons to be stated: Questions

Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
The entity does not consider the Principles material to its business (Yes/No)	NA	NA	NA	NA	NA	NA	NA	NA	NA
The entity is not at a stage where it is in a position to formulate and implement the policies on specified principles (Yes/No)					NA				
The entity does not have the financial or/human and technical resources available for the task (Yes/No)	NA	NA	NA	NA	NA	NA	NA	NA	NA
It is planned to be done in the next financial year (Yes/No)	NA	NA	NA	NA	NA	NA	NA	NA	NA
Any other reason (please specify)					NA				

Section C) PRINCIPLE WISE PERFORMANCE DISCLOSURE

This section is aimed at helping entities demonstrate their performance in integrating the Principles and Core Elements with key processes and decisions. The information sought is categorized as “Essential” and “Leadership”. While the essential indicators are expected to be disclosed by every entity that is mandated to file this report, the leadership indicators may be voluntarily disclosed by entities which aspire to progress to a higher level in their quest to be socially, environmentally and ethically responsible.

Principle 1. Businesses should Conduct and Govern themselves with integrity and in a manner that is ethical, transparent and accountable.**Essential Indicators:**

1. Percentage coverage by training and awareness programmes on any of the Principles during the financial year:

Segment	Total Number of training and awareness programmes held	Topics / principles covered under the training and its impact	% of persons in respective category covered by the awareness programmes
Board of Directors	1	Anti Bribery and Anti Corruption Policy	100%
Key Managerial Personnel	1	Anti Bribery and Anti Corruption Policy	100%
Employees other than BoD and KMPs	4	Anti Bribery and Anti Corruption Policy POSH Act Grievance Redressal Mechanism Importance of Stakeholders	100%
Workers	2	All workers undergo a toolbox talk and learnings from incident sessions	100%

2. Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the following format (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed on the entity's website):

A. Monetary

Particulars	NGRBC Principle	Name of the regulatory / Enforcement agencies/ judicial institutions	Amount (In Rs.)	Brief of the Case	Has an appeal been preferred ? (Yes/No)
Penalty/Fine	Nil	Nil	Nil	Nil	Nil
Settlement	Nil	Nil	Nil	Nil	Nil
Compounding Fee	Nil	Nil	Nil	Nil	Nil

B. Non Monetary

Particulars	NGRBC Principle	Name of the regulatory / Enforcement agencies/judicial institutions	Brief of the Case	Has an appeal been preferred ? Yes/No
Imprisonment	Nil	Nil	Nil	Nil
Punishment	Nil	Nil	Nil	Nil

3. Of the instances disclosed in Question 2 above, details of the Appeal/ Revision are preferred in cases where monetary or non-monetary action has been appealed.

Case Details	Name of the regulatory /enforcement agencies/judicial institutions
Not Applicable	

4. Does the entity have an anti-corruption or anti-bribery policy? If yes, provide the details in brief and if available, provide a web-link to the policy.

Yes, Company has an anti – corruption and anti-bribery policy. The Company recognises and follows all applicable laws and regulations and respects lawful customs of the regions where we operate and transact. We are committed to acting and building relationship based on integrity and fairness in all our dealings. Hence, Balaxi has adopted a "Zero Tolerance" approach to bribery and corruption. The policy is available on the website of the company at https://balaxipharma.in/assets/images/corporatepolicies/BRSR_Policy.pdf

5. Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:

	FY 2026	FY 2025
Directors	Nil	Nil
KMPs	Nil	Nil
Employees	Nil	Nil
Workers	Nil	NA

6. Details of complaints with regard to conflict of interest

Particulars	FY 2026		FY 2025	
	Number	Remarks	Number	Remarks
Number of complaints received in relation to issues of Conflict of Interest of the Directors	-	-	-	-
Number of complaints received in relation to issues of Conflict of Interest of the KMPs	-	-	-	-

7. Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.

Not Applicable

8. Number of days of accounts payables ((Accounts payable *365) / Cost of goods/services procured) in the following format:

	FY 2026	FY 2025
Number of days of accounts payables	95	64

9. Open-ness of business

Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along-with loans and advances & investments, with related parties, in the following format

Parameter	Metrics	FY 2026	FY 2025
Concentration of Purchases	a. Purchases from trading houses as % of total purchases	Nil	Nil
	b. Number of trading houses where purchases are made from	Nil	Nil
	c. Purchases from top 10 trading houses as % of total purchases from trading houses.	Nil	Nil
Concentration of Sales	a. Sales to dealers /distributors as % of total sales	Nil	Nil
	b. Number of dealers/ distributors to whom sales are made	Nil	Nil
	c. Sales to top 10 dealers/distributors as % of total sales to dealers/distributors	Nil	Nil
Share of RPTS in	a. Purchases (purchases with related parties/Total purchases)	N/A	Nil
	b. Sales (Sales to related parties/Total Sales)	8085.11 Lakhs	Nil
	c. Loans and advances (Loans and advances given to related parties/Total loans and advances)	N/A	Nil
	d. Investments (Investments in related parties/Total investments made)	5444.10 Lakhs	Nil

Principle 2. Businesses should provide goods and services in a manner that is sustainable and safe.

Essential Indicators:

- Percentage of R&D and capital expenditure (CAPEX) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.

Category	Current Financial Year	Previous Financial Year	Details of improvements in environmental and social impacts
R&D	Nil*	Nil*	-
Capex	Nil*	Nil*	-

*As on March 31, 2026 the Company is operating on an asset-light model and hence, no capex has been incurred by the Company.

In case the entity desires to disclose any benefits other than those specified in this field, additional columns may be added for such disclosures.

- Does the entity have procedures in place for sustainable sourcing? (Yes/No)
Yes, we have GMP certified Contract Development Manufacturing Organizations ("CDMOs")
 - If yes, what percentage of inputs were sourced sustainably?
100 % of our products are sourced from GMP Certified CDMOs.
- Describe the processes in place to reclaim products for reusing, recycling, and disposing at the end of life for
 - Plastics (Including Packaging) :Yes
 - E-Waste:Yes
 - Hazardous waste: Yes
 - other waste :Yes

We ensure that the products are disposed off/reused/recycled, as per the nature of the product at the end of the life cycle in respective markets.

4. Extended Producer Responsibility (EPR)

Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities (Yes / No). If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? If not, steps taken to address the same.

Not applicable. Company is not involved in any manufacturing activity as on 31st March, 2026. The Company is engaged in the business of International Wholesale Distribution in various international markets.

However, Manufacturing facility has been established in which operations are expected to commence in H1 of FY 2026-27.

PRINCIPLE 3 Businesses should respect and promote the well-being of all employees, including those in their value chains**1. ESSENTIAL INDICATORS:**

a. Details of measures for the well-being of employees

Category	% of employees covered by										
	Total A	Health Insurance		Accident insurance		Maternity Benefits		Paternity Benefits		Day Care Facilities	
		Number B	% (B/A)	Number C	% (C/A)	Number D	% (D/A)	Number E	% (E/A)	Number F	% (F/A)
Permanent Employees											
Male	51	27	52.94	27	52.94	0	0	0	0	0	0
Female	11	0	0	0	0	0	0	0	0	0	0
Total	62	27	43.55	27	43.55	0	0	0	0	0	0
Other than permanent employees											
Male	0	0	0	0	0	0	0	0	0	0	0
Female	0	0	0	0	0	0	0	0	0	0	0
Total	0	0	0	0	0	0	0	0	0	0	0

In case the entity desires to disclose any benefits other than those specified in this field, additional columns may be added for such disclosures.

b. Details of measures for the well-being of Workers

Category	% of workers covered by										
	Total A	Health Insurance		Accident insurance		Maternity Benefits		Paternity Benefits		Day Care Facilities	
		Number B	% (B/A)	Number C	% (C/A)	Number D	% (D/A)	Number E	% (E/A)	Number F	% (F/A)
Permanent workers											
Male	6	0	0	0	0	0	0	0	0	0	0
Female	1	0	0	0	0	0	0	0	0	0	0
Total	7	0	0	0	0	0	0	0	0	0	0
Other than permanent workers											
Male	0	0	0	0	0	0	0	0	0	0	0
Female	0	0	0	0	0	0	0	0	0	0	0
Total	0	0	0	0	0	0	0	0	0	0	0

In case the entity desires to disclose any benefits other than those specified in this field, additional columns may be added for such disclosures.

- c. Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format –

	FY 2026 Current Financial Year	FY 2025 Previous Financial Year
Cost incurred on well-being measures as a % of total revenue of the company	Rs 2,95,100/-	Nil

2. Details of retirement benefits, for current FY and previous financial year

Benefits	FY 2026			FY 2025		
	Number of employees covered as % of total employees	Number of Workers covered as % of total employees	Deducted and deposited with the authority (Y/N/N.A)	Number of employees covered as % of total employees	Number of Workers covered as % of total employees	Deducted and deposited with the authority (Y/N/N.A)
PF	100%	100%	Y	100%	NA	Yes
Gratuity	100%	100%	Y	100%	NA	Yes
ESI	21.31%	71.42%	Y	16.66%	NA	Yes
Others – specify	-	-	-	-	-	-

3. Accessibility of workplaces

Are the premises / offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard.

Yes, the office of the Company is accessible to differently abled employees.

4. Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web-link to the policy.

Yes, the policy is available on the website of the company at <https://balaxipharma.in/corporate-policies>

5. Return to work and Retention rates of permanent employees and workers that took parental leave.

Gender	Permanent Employees		Permanent Workers	
	Return to work Rate	Retention Rate	Return to work Rate	Retention rate
Male	-	-	-	-
Female	-	-	-	-
Total	-	-	-	-

6. Is there a mechanism available to receive and redress grievances for the following categories of employees and worker? If yes, give details of the mechanism in brief.

Particulars	Yes/No (if yes then give details of the mechanism in brief)
Permanent Workers	Yes,
Other than Permanent Workers	The Company has a Grievance Redressal policy, which address all kinds of issues an employee may face while at work. The grievance may include: 1. Any kind of discrimination on account of disability, gender, race, sexual orientation, religion, marital status and social class 2. Violation of human rights 3. Bullying / workplace harassment 4. Denial of applicable benefits, 5. Working conditions
Permanent Employees	
Other than permanent Employees	Not Applicable

7. Membership of employees and worker in association(s) or Unions recognised by the listed entity:

Category	FY 2026			FY 2025		
	Total employees / workers in respective category (A)	Total employees/ workers in respective category, who are part of association (s) or Union (s)	% B/A	Total employees / workers in respective category (A)	Total employees/ workers in respective category, who are part of association (s) or Union (s)	% B/A
Total Permanent Employees						
Male	51	0	0	0	0	0
Female	11	0	0	0	0	0
Total Permanent Workers						
Male	6	0	0	NA	NA	NA
Female	1	0	0	NA	NA	NA

8. Details of Training imparted to the employees and workers on health & safety measures and on skill upgradation

Category	FY 2026					FY 2025				
	Total (A)	On health and safety Measures		On skill upgradation		Total (D)	On health and safety Measures		On skill upgradation	
		NO. B	% (B/A)	No.C	% (C/A)		No. (E)	% (E/D)	No.(F)	%(F/D)
Employees										
Male	51	51	100	51	100	23	23	100	23	100
Female	11	11	100	11	100	0	0	0	0	0
Total	62	62	100	62	100	23	23	100	23	100
Workers										
Male	6	6	100	6	100	NA	NA	NA	NA	NA
Female	1	1	100	1	100	NA	NA	NA	NA	NA
Total	7	7	100	7	100	NA	NA	NA	NA	NA

9. Details of performance and career development reviews of employees and workers:

Category	FY 2026			FY 2025		
	Total (A)	No.(B)	% (B/A)	Total C	No.(D)	% (D/C)
Employees						
Male	51	51	100	23	23	100
Female	11	11	100	0	0	0
Total	62	62	100	23	23	100
Workers						
Male	6	6	100	NA	NA	NA
Female	1	1	100	NA	NA	NA
Total	7	7	100	NA	NA	NA

10. Health and safety management system

- a. Whether an occupational health and safety management system has been implemented by the entity? **(Yes/ No)**. If yes, the coverage such system?

Yes, the company has implemented the Health and Safety Policy which covers all the employees of the Company.

- b. What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?

Appropriate policies / guidelines have been formulated to address various types of hazards and related risk assessment & mitigation.

- All work-related hazards are identified basis the recommended guidelines.
- Their associated risk assessment procedures are part of the Safety manual.

- c. Whether you have processes for workers to report the work-related hazards and to remove themselves from such risks. **(Y/N)**

Yes

- d. Do the employees/ worker of the entity have access to non-occupational medical and healthcare services? **(Yes/No)**

Yes

11. Details of safety related incidents

Safety Incident / Number	Category	FY 2026	FY 2025
Lost Time Injury Frequency Rate (LTIFR) Per One million -person hours worked	Employees	0	0
	Workers	0	NA
Total recordable work-related injuries	Employees	0	0
	Workers	0	NA
No of fatalities	Employees	0	0
	Workers	0	NA
High consequence work-related injury or ill-health (excluding fatalities)	Employees	0	0
	Workers	0	NA

12. Describe the measures taken by the entity to ensure a safe and healthy work-place.

Employee well-being programs/initiatives were conducted for all the employees during FY 2025-26. The following well-being initiatives were undertaken:

- Women safety programs
- POSH and gender sensitization meetings
- Road safety programs
- Women self-defense program
- Fire emergency training exit
- General health check up

13. Number of complaints made by employees and workers

	FY 2026			FY 2025		
	Filed during the year	Pending resolutions at the end of the year	Remarks	Filed during the year	Pending resolutions at the end of the year	Remarks
Working Conditions	NIL	NIL	NIL	NIL	NIL	NIL
Health & Safety	NIL	NIL	NIL	NIL	NIL	NIL

14. Assessments for the year

Particulars	% of plants and offices that were assessed (By entity or statutory authorities or third parties)
Health and safety practices	100%
Working Conditions	100%

15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks / concerns arising from assessments of health & safety practices and working conditions.

The Company has implemented Hygiene Policy which ensures workplace cleanliness and basic amenities like availability of clean drinking water, proper sanitation facilities, etc.

The HR team conducts review on a quarterly basis to ensure all the points under the hygiene policy are taken care of. Further, training of all employees regarding protocol to be followed in case of any safety incident has been conducted.

Principle 4. Businesses should respect the interests of and be responsive to all its stakeholders.

Essential Indicators:

1. Describe the process for identification of key stakeholder groups of the entity.

Balaxi, a pharmaceutical distribution company, effectively identifies its stakeholders through meticulous research and analysis. Senior management and HODs of the respective departments interact with the respective stakeholders before forming an association. Primary stakeholders such as customers, suppliers, employees, workers and investors are recognized, understanding their needs and expectations accordingly. The WHO GMP certified units from which Balaxi procures products are also considered stakeholders, ensuring high-quality standards.

2. List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.

Stakeholder Group	Whether identified as Vulnerable & Marginalized Group (Yes/ No)	Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website, Other)	Frequency of engagement (Annually/ Half yearly/ Quarterly / others – please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
Customers (Distributors, Wholesalers and Retailers)	No	- satisfaction surveys - Marketing and advertising - Complaint handling and feedback - Electronic communication – social media, Calls.	It is a continuous process	Addressing requirements for products and grievances, if any
Suppliers/ CDMOs	No	- Regular interaction through online and offline meetings, phone calls, e-mails - Conferences and workshops - In Person Meetings/ Visits.	Daily	To share the specific requirements, Status update on product deliveries and other terms of trade.
Employees	No	- Trainings and development programmes - Performance management system. - Emails. Written communication - circulars and internal publications - Employee engagement initiatives.	Daily/ Weekly	For smooth functioning of business operations.
Investors	No	- Annual General meeting - Investor presentations and conference calls. - Investor conferences and meets. - Press releases, Quarterly Results and newsletters.	Quarterly/ Annually/ Need basis	To provide updates on company's operations and Financial Performance
Government/ regulators	No	- Meetings and formal dialogue - Filings with the regulators.	Others – Need Basis	Business and compliance related
Community	Yes	CSR partnerships - Contribution towards various causes	Others- Need basis	CSR Initiatives of the Company

Principle 5. Businesses should respect and promote human rights.**Essential Indicators**

1. Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following format:

Category	FY 2026 Current financial Year			FY 2025 Previous Financial Year		
	Total (A)	Number of employees and workers covered (B)	% (B/A)	Total (C)	Number of employees and workers covered (D)	% (D/C)
Employees						
Permanent	62	62	100	48	48	100
Other than Permanent	-	-	-	0	0	0
Total Employees	62	62	100	48	48	100
Workers						
Permanent	7	7	100	-	-	-
Other than permanent	-	-	-	-	-	-
Total Workers	7	7	100	-	-	-

2. Details of minimum wages paid to employees and workers, in the following format

Category	FY 2026					FY 2025				
	Total (A)	Equal to Minimum Wage		More than Minimum Wage		Total (D)	Equal Minimum Wage		More than minimum wage	
		No.(B)	%(B/A)	No.(C)	%(C/A)		No. (E)	%(E/D)	No.(F)	%(F/D)
Employees										
Permanent										
Male	51	0	0	46	90.19	43	0	0	43	100
Female	11	0	0	1	9.09	5	0	0	5	100
Other than Permanent										
Male	-	-	-	-	-	-	-	-	-	-
Female	-	-	-	-	-	-	-	-	-	-
Workers										
Permanent										
Male	6	0	0	1	16.66	NA	NA	NA	NA	NA
Female	1	0	0	0	0	NA	NA	NA	NA	NA
Other than Permanent										
Male	-	-	-	-	-	NA	NA	NA	NA	NA
Female	-	-	-	-	-	NA	NA	NA	NA	NA

3. Details of remuneration/ salary/ wages (including differently abled)

a. Median Remuneration / Wages:

Category	Male		Female	
	Number	Median remuneration/ salary/wages of respective category (₹ In Lakhs)	Number	Median remuneration/ salary/wages of respective category (₹ In Lakhs)
Board of Directors	4	2.5	2	2.5
Key Managerial Personnel	4	28.17	0	-
Employees other than BoD and KMP	49	5.52	11	2.24
Workers	6	2.24	1	2.01

b. Gross wages paid to females as % of total wages paid by the entity, in the following format:

	FY 2026 Current financial Year	FY 2025 Previous Financial Year
Gross wages paid to females	Rs. 24,45,000	NA
Total wages	Rs. 5,24,45,736	NA
Gross wages paid to females (Gross wages paid to females as % of total wages)	4.66%	NA

4. Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)

Yes

5. Describe the internal mechanisms in place to redress grievances related to human rights issues.

Company is committed to providing a safe and positive work environment. In keeping with this philosophy, the organization has an open-door policy. Employees also have access to Human Resource Department where they can highlight matters or concerns faced at the workplace. This is achieved through a well-established and robust grievance resolution mechanism comprising of Internal Resolution Committee. Internal Resolution Committee adhere to the principles of natural justice, confidentiality, sensitivity, non-retaliation and fairness while addressing concerns. The concerns are handled with sensitivity, while delivering timely action and closure.

6. Disclosure of complaints made by employees and workers on sexual harassment, discrimination at workplace, Child Labour, Forced Labour/Involuntary Labour, Wages or other human rights related issues.

Category	FY 2025-26 Current Financial Year			FY2024-25 Previous Financial Year		
	Filed during the day	Pending Resolution at the end of the year	Remarks	Filed During the Year	Pending Resolution at the end of the year	Remarks
Sexual Harassment	Nil	Nil	Nil	Nil	Nil	Nil
Discrimination at workplace	Nil	Nil	Nil	Nil	Nil	Nil
Forced Labour/Involuntary Labour	Nil	Nil	Nil	Nil	Nil	Nil
Wages	Nil	Nil	Nil	Nil	Nil	Nil
Other human right related issues	Nil	Nil	Nil	Nil	Nil	Nil

7. Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, in the following format:

	FY 2026	FY 2025
Total Complaints reported under Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)	NIL	NIL
Complaints on POSH as a % of female employees / workers	NIL	NIL
Complaints on POSH upheld	NIL	NIL

8. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.

Company is committed to providing a safe and positive work environment. In keeping with this philosophy, the organization has an open-door policy. Employees also have access to Human Resource Department where they can highlight matters or concerns faced at the workplace. This is achieved through a well-established and robust grievance resolution mechanism comprising of Internal Resolution Committee. Internal Resolution Committee adhere to the principles of natural justice, confidentiality, sensitivity, non-retaliation and fairness while addressing concerns. The concerns are handled with sensitivity, while delivering timely action and closure.

9. Do human rights requirements form part of your business agreements and contracts? (Yes/No) : Yes

10. Assessments of the year

Category	% of plants and offices that were assessed (by the entity or by the statutory authorities or third parties)
Child Labour	100%
Forced/Involuntary Labour	100%
Sexual harassment	100%
Discrimination at workplace	100%
Wages	100%
Others – please specify	NA

11. Provide the details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 10 above.

No significant risks reported in the assessment.

Principle 6. Businesses should respect and make efforts to protect and restore the environment.**Essential Indicators:**

1. Details of total energy consumption (in Joules or multiples) and energy intensity

Parameter	FY 2026 (in Giga Joules)	FY 2025 (in Giga Joules)
From renewable sources		
Total electricity consumption (A)	Nil	Nil
Total fuel consumption (B)	Nil	Nil
Energy consumption through other sources (C)	Nil	Nil
Total energy consumed from renewable resources (A+B+C)	Nil	Nil
From non-renewable sources		
Total electricity consumption (D)	1391.82	113.86
Total fuel consumption (E)	Nil	Nil
Energy consumption through other sources (F)	Nil	Nil
Total energy consumed from non-renewable resources (D+E+F)	1391.82	113.86
Total energy consumed. (A+B+C+D+E+F)	1391.82	113.86
Energy intensity per rupee of turnover (Total energy consumption/ turnover in rupees)	0.172 GJ/Rs. Lakhs	0.011 GJ/Rs. Lakhs
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total energy consumed / Revenue from operations adjusted for PPP)	NA	NA
Energy intensity in terms of physical output	NA	NA
Energy intensity (<i>optional</i>) – the relevant metric may be selected by the entity	NA	NA

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

No

2. Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Y/N). If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, the remedial action taken, if any.

No

3. Provide details of the following disclosures related to water, in the following format

Parameter	FY 2026	FY 2025
Water Withdrawal by Source (In Kiloliters)		
(i) Surface water	NA	NA
(ii) Groundwater	-	1388
(iii) Third party water	2962	-
(iv) Seawater / desalinated water	-	-
(v) Others	-	-
Total volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)	2962	1388
Total volume of water consumption (in kilolitres)	2962	1388
Water intensity per rupee of turnover (Water consumed / Revenue from operations)	0.36 KI/Rs. Lakhs	0.14 KI/Rs.Lakhs
Water intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total water consumption / Revenue from operations adjusted for PPP)	NA	NA
Water intensity in terms of physical output	NA	NA
Water intensity (optional) – the relevant metric may be selected by the entity	NA	NA

Note - Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) . If yes, name of the external agency

No

4. Provide the following details related to water discharge –

Parameter	FY 2026 (Current Financial Year)	FY 2025 (Previous Financial Year)
Water discharge by destination and level of treatment (in kilolitres)		
(i) To Surface water		
- No treatment		
- With treatment – please specify level of treatment		
(ii) To Groundwater		
- No treatment		
- With treatment – please specify level of treatment		
(iii) To Seawater		
- No treatment	Nil	Nil
- With treatment – please specify level of treatment		
(iv) Sent to third-parties		
- No treatment		
- With treatment – please specify level of treatment		
(v) Others		
- No treatment		
- With treatment – please specify level of treatment		
Total water discharged (in kilolitres)		

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

No

5. Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation.

Zero Liquid Discharge is not applicable to the Company for Financial Year 2025-26 as the operations of the Company are limited to International Wholesale Distribution.

However, Manufacturing facility has been established in which operations are expected to commence in H1 of FY 2026-27.

6. Please provide the details of air emissions (other than GHG emissions) by the entity, in the following format -

Parameter	Please specify unit	FY 2026	FY 2025
NOx		Nil	Nil
Sox		Nil	Nil
Particulate Mater		Nil	Nil
Persistent organic pollutants (POP)		Nil	Nil
Volatile organic compounds (VOC)		Nil	Nil
Hazardous air pollutants (HAP)		Nil	Nil
Others – please specify		Nil	Nil

With respect to Financial Year 2025-26, the Company was not into manufacturing and therefore the possibility of releasing emissions into the atmosphere is negligible/not applicable

However, Manufacturing facility has been established in which operations are expected to commence in H1 of FY 2026-27.

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency

No

7. Please provide the details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & their intensity

Parameter	Unit	FY 2026	FY 2025
Total Scope 1 emissions (Break-up of the GHG into CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ , NF ₃ , if available)	Metric tonnes of CO₂ equivalent	2.11325 tCO₂e	Nil
Total Scope 2 emissions (Break-up of the GHG into CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ , NF ₃ , if available)	Metric tonnes of CO₂ equivalent	274.497786 tCO₂e	25.30 tCO₂e
Total Scope 1 and Scope 2 emissions intensity per rupee of turnover (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations)	Metric tonnes of CO₂ equivalent	0.000000342 tCO₂e	-
Total Scope 1 and Scope 2 emission intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations adjusted for PPP)	Nil	Nil	Nil
Total Scope 1 and Scope 2 emission intensity in terms of physical output	Nil	Nil	Nil
Total Scope 1 and Scope 2 emission intensity (optional) – the relevant metric may be selected by the entity	Nil	Nil	Nil

With respect to Financial Year 2025-26, the Company was not into manufacturing and therefore the possibility of releasing greenhouse gas emissions into the atmosphere is negligible/not applicable.

However, Manufacturing facility has been established in which operations are expected to commence in H1 of FY 2026-27.

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency

No

8. Does the entity have any project related to reducing Green House Gas emission? If yes, then provide the details.

No

9. Provide details related to waste management by entity , in the following format

Parameter	FY 2026	FY 2025
Total Waste generated (in metric tonnes)		
Plastic waste (A)	0.112	Nil
E-waste (B)	Nil	Nil
Bio-medical waste (C)	0.084	Nil
Construction and demolition waste (D)	Nil	Nil
Battery waste (E)	Nil	Nil
Radioactive waste (F)	Nil	Nil
Other Hazardous waste (G). Please specify if any	Nil	Nil
Other Non-hazardous waste generated (H) (Break-up by composition i.e by materials relevant to the sector)	Nil	Nil
Total (A+B+C+D+E+F+G+H)	Nil	Nil
Waste intensity per rupee of Turnover (Total waste generated / Revenue from operations)	Nil	Nil
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)(Total waste generated / Revenue from operations adjusted for PPP)	Nil	Nil
Waste intensity in terms of physical output	Nil	Nil
Waste intensity (optional) – the relevant metric may be selected by the entity	Nil	Nil
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)		
Category of waste		
i. Re-cycled	Nil	Nil
ii. Re-used	Nil	Nil
iii. Other recovery operations	Nil	Nil
Total	Nil	Nil
For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes)		
Category of Waste		
i. Incineration	Nil	Nil
ii. Landfilling	Nil	Nil
iii. Other disposal operations	Nil	Nil
Total	Nil	Nil

Note: With respect to Financial Year 2025-26, the nature of business of the Company was limited to International Wholesale Distribution. However, the company executed validation batches in the month of September 2025. The manufacturing facility has dust extraction system in place to avoid significant environmental impact or change in nature attributable to the operations.

However, Commercial product Manufacturing in the facility is expected to commence in H1 of FY 2026-27.

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) . If yes, name of the external agency

No

10. Briefly describe the details of waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes.

The company executed validation batches in the month of September 2025. The manufacturing facility has dust extraction system in place to avoid significant environmental impact or change in nature.

The facility has not used any toxic material for validation batches, waste generated during processing was handled with authorized contractor for ETP waste disposal.

We have received the Certificate of Consent HW authorization order-Orange Category from the Telangana State Pollution Control Board, Zonal Office, Hyderabad (Order No.: 1059-MBNR/TSPCB/ZOH/TS-Ipass/CFO/2025-1585). In addition, an agreement has been executed with an authorized biomedical waste management agency, and arrangements are in place for the safe disposal of scrapped materials and canteen food waste.

11. If the entity has operations/offices if any in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals / clearances are required,

S. No.	Location of operations/offices	Type of operations	Whether the conditions of environmental approval / clearance are being complied with? (Y/N) If no, the reasons thereof and corrective action taken, if any.
--------	--------------------------------	--------------------	--

Not Applicable

12. Details of environmental impact assessments (EIA) of projects undertaken by the entity based on applicable laws, in the current financial year:

During the reporting period, the Company has not conducted any environment impact assessment. Company ensures compliance to local and national laws wherever required.

Name and brief details of project	EIA Notification No.	Date	Whether conducted by independent external agency (Yes / No)	Results communicated in public domain (Yes / No)	Relevant Web Link
-----------------------------------	----------------------	------	---	--	-------------------

Not Applicable

13. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India, such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format:

Yes

SL No	Specify the Law / regulation / guidelines which was not complied with	Provide details of the non-compliance	Any fines / penalties / action taken by regulatory agencies such as pollution control boards or by courts	Corrective action taken, if any
-------	---	---------------------------------------	---	---------------------------------

Not Applicable

Principle 7. Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent.

Essential Indicators

- 1 a. Number of affiliations with trade and industry chambers/associations. 5
- b. List the top 10 trade and industry chambers/associations (determined based on the total members of such body) the entity is a member of /affiliated to

SL No	Name of the trade industry chambers/associations	The reach of trade and industry chambers/associations (State/National)
1	Two Star Export House Certificate by Directorate General of Foreign trade	National
2	Pharmexcil Registration from Pharmaceuticals Export Promotion Council of India	National
3	FSSAI Certification from Food Safety and Standards Authority of India (FSSAI)	National
4	Certification from Agricultural and Processed Food Products Export Development Authority (APEDA)	National
5	Member of Federation of Indian Export Organisation (FIEO)	National

2. Provide Details of corrective action taken or underway on any issues related to anticompetitive conduct by the entity, based on adverse orders from regular authorities.

Name of authority	Brief of the case	Corrective actions taken
NIL		

Principle 8. Businesses should promote inclusive growth and equitable development

Essential Indicators

- Details of social impact assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year.

Name and brief details of the project	SIA notification No.	Date of notification	Whether conducted by an Independent external agency (Yes/No)	Results communicated in public domain (Yes/ No)	Relevant weblink
---------------------------------------	----------------------	----------------------	--	---	------------------

Not Applicable

- Information on project (s) for which ongoing rehabilitation and resettlement (R&R) is being undertaken by the entity, in the following format -

SL No	Name of project for which R&R is ongoing	State	District	No. of project-affected families	% of PAFs covered by R&R	Amount paid to PAFs in FY (In INR)
-------	--	-------	----------	----------------------------------	--------------------------	------------------------------------

Not Applicable

- Describe the mechanisms to receive and redress grievances of the community

We have a grievance redressal mechanism which covers all our stakeholders. Active engagement with the community and stakeholders requires an effective grievance redressal system that includes feedback loops and conflict resolution mechanisms. Stakeholders can share their feedback/ concern on info@balaxipharma.in

- Percentage of input material (inputs to total inputs by value) sourced from suppliers

Particulars	FY 2026	FY 2025
Directly sourced from MSMEs/small producers	99%	96.04%
Directly from within India	-	-

- Job creation in smaller towns – Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis) in the following locations, as % of total wage cost

Location	FY 2025-26 (Current Financial Year)	FY 2024-25 (Previous Financial Year)
Rural	-	-
Semi-Urban	25.94%	-
Urban	-	-
Metropolitan	74.06%	-

(Place to be categorized as per RBI Classification System - rural / semi-urban / urban / metropolitan)

Principle 9. Businesses should engage with and provide value to their consumers in a responsible manner.**Essential Indicators**

- Describe the mechanism in place to receive and respond to consumer complaints and feedback
Consumers can directly contact the Company through email or phone and further our representative visits all the clients regularly for their feedback and issues, if any.

- Turnover of products and /services as a percentage of turnover from all products/service that carry information about

Particulars	As a % of total turnover
Environmental and social parameters relevant to the product	100
Safe and responsible usage	100
Recycling and/or safe disposal	100

- Number of consumer complaints in respect of the following

Particulars	FY 2026		Remarks	FY 2025		Remarks
	Received during the year	Pending resolution at end of year		Received during the year	Pending resolution at end of year	
Data Privacy	0	0		0	0	
Advertising	0	0		0	0	
Cyber-security	0	0		0	0	
Delivery of essential services	0	0		0	0	
Restrictive Trade Practices	0	0		0	0	
Unfair Trade Practices	0	0		0	0	
Other	0	0		0	0	

- Details of instances of product recalls on account of safety issues:

Particulars	Number	Reasons for recall
Voluntary recalls	0	N.A
Forced recalls	0	N.A

- Does the entity have Framework/ policy on cyber security and risks related to data privacy? **(Yes/No)** If available, web-link of the policy.
Yes, the policy is available at <https://balaxipharma.in/corporate-policies>.
- Provide Details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services. :None
- Provide the following information relating to data breaches:
 - Number of instances of data breaches : None
 - Percentage of data breaches involving personally identifiable information of customers: None
 - Impact, if any, of the data breaches: None